Next |
home / stock / heb / heb message board
Subject | By | Source | When |
---|---|---|---|
Hemispherx Biopharma ($HEB) | mick | investorshub | 11/05/2020 3:36:39 PM |
I liked the original name better lol. Still | Richard2 | investorshub | 11/05/2020 2:30:40 PM |
Hemispherx Biopharma (HEB)$ NOW $AIM | mick | investorshub | 04/05/2020 8:08:00 PM |
Thank you Richard, I couldn't seem to find | deniseann | investorshub | 02/05/2020 4:37:21 PM |
$AIM is the new ticker. | Richard2 | investorshub | 02/05/2020 9:43:25 AM |
No, the company changed its name and ticker. | Richard2 | investorshub | 02/05/2020 9:42:13 AM |
Is this still a real stock..? | deniseann | investorshub | 01/30/2020 5:25:12 PM |
Buying all i can it may be a | lowfloatwayne | investorshub | 11/06/2019 11:36:32 PM |
This drug could be huge in the me/cfs | Richard2 | investorshub | 10/28/2019 3:17:30 PM |
They need cash so they can hit their | LW89 | investorshub | 08/29/2019 9:42:17 PM |
Their voting now to raise the share count | lowfloatwayne | investorshub | 08/28/2019 1:00:51 PM |
Acusphere has twice as many shares moves ez | lowfloatwayne | investorshub | 08/27/2019 1:11:15 AM |
this is just sad. pure sad | cspratt15139 | investorshub | 08/18/2019 12:56:54 PM |
Ok their not adding shares could be a | lowfloatwayne | investorshub | 08/06/2019 1:35:14 AM |
they do this to themselves | cspratt15139 | investorshub | 07/24/2019 12:36:48 AM |
So they rs to 2.2m shares then dilute | lowfloatwayne | investorshub | 07/23/2019 1:48:54 AM |
strong buy here. Bottom bouncer. | aristotelisonassis | investorshub | 07/17/2019 6:06:48 PM |
Hope everyone is enjoying there weekend. Stay safe | cspratt15139 | investorshub | 06/22/2019 8:18:43 PM |
Ampligen is picking up steam | cspratt15139 | investorshub | 06/16/2019 8:15:04 PM |
Fully funded trial up to 45-people, low float, | bleu22 | investorshub | 06/16/2019 7:56:04 PM |
News, Short Squeeze, Breakout and More Instantly...
Hemispherx BioPharma Inc. Company Name:
HEB Stock Symbol:
NYSE Market:
Hemispherx BioPharma Inc. Website:
OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic...
OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the ...
OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB ) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovar...